Phaseline

Companies › Pathos AI

Pathos AI: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pocenbrodib
Selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on hi
CREBBP, EP300Phase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06785636PocenbrodibPhase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)OncologyJun 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CREBBP (1) EP300 (1)

Companies with the same targets

Opna Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.